Literature DB >> 34071162

The Non-Coding RNA Landscape in IgA Nephropathy-Where Are We in 2021?

Izabella Z A Pawluczyk1, Haresh Selvaskandan1, Jonathan Barratt1.   

Abstract

IgA nephropathy (IgAN) is the most commonly diagnosed primary glomerulonephritis worldwide. It is a slow progressing disease with approximately 30% of cases reaching end-stage kidney disease within 20 years of diagnosis. It is currently only diagnosed by an invasive biopsy and treatment options are limited. However, the current surge in interest in RNA interference is opening up new horizons for the use of this new technology in the field of IgAN management. A greater understanding of the fundamentals of RNA interference offers exciting possibilities both for biomarker discovery and, more importantly, for novel therapeutic approaches to target key pathogenic pathways in IgAN. This review aims to summarise the RNA interference literature in the context of microRNAs and their association with the multifaceted aspects of IgA nephropathy.

Entities:  

Keywords:  IgA nephropathy; RNA interference; microRNA

Year:  2021        PMID: 34071162     DOI: 10.3390/jcm10112369

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  125 in total

Review 1.  miRNAs on the move: miRNA biogenesis and the RNAi machinery.

Authors:  Elizabeth P Murchison; Gregory J Hannon
Journal:  Curr Opin Cell Biol       Date:  2004-06       Impact factor: 8.382

2.  Predicting renal outcome in IgA nephropathy.

Authors:  M G Radford; J V Donadio; E J Bergstralh; J P Grande
Journal:  J Am Soc Nephrol       Date:  1997-02       Impact factor: 10.121

3.  GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.

Authors:  Lesley A Inker; Hiddo J L Heerspink; Hocine Tighiouart; Andrew S Levey; Josef Coresh; Ron T Gansevoort; Andrew L Simon; Jian Ying; Gerald J Beck; Christoph Wanner; Jürgen Floege; Philip Kam-Tao Li; Vlado Perkovic; Edward F Vonesh; Tom Greene
Journal:  J Am Soc Nephrol       Date:  2019-07-10       Impact factor: 10.121

4.  Proliferation and Cytokine Production of Human Mesangial Cells Stimulated by Secretory IgA Isolated from Patients with IgA Nephropathy.

Authors:  Yan Liang; Junjun Zhang; Yali Zhou; Guolan Xing; Guoqiang Zhao; Zhangsuo Liu
Journal:  Cell Physiol Biochem       Date:  2015

5.  Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs.

Authors:  Lee P Lim; Nelson C Lau; Philip Garrett-Engele; Andrew Grimson; Janell M Schelter; John Castle; David P Bartel; Peter S Linsley; Jason M Johnson
Journal:  Nature       Date:  2005-01-30       Impact factor: 49.962

6.  Predictors of outcome for severe IgA Nephropathy in a multi-ethnic U.S. cohort.

Authors:  Ana Huerta Arroyo; Andrew S Bomback; Blake Butler; Jai Radhakrishnan; Leal Herlitz; M Barry Stokes; Vivette D'Agati; Glen S Markowitz; Gerald B Appel; Pietro A Canetta
Journal:  Clin Nephrol       Date:  2015-09       Impact factor: 0.975

Review 7.  MicroRNA and cancer.

Authors:  Martin D Jansson; Anders H Lund
Journal:  Mol Oncol       Date:  2012-10-09       Impact factor: 6.603

Review 8.  Liver-specific microRNA-122: Biogenesis and function.

Authors:  Catherine Jopling
Journal:  RNA Biol       Date:  2012-02-01       Impact factor: 4.652

9.  Genetic Variation in miR-146a Is Not Associated with Susceptibility to IgA Nephropathy in Adults from a Chinese Han Population.

Authors:  Bin Yang; Wei Wei; Yunying Shi; Zhuochun Huang; Bei Cai; Junlong Zhang; Binwu Ying; Lanlan Wang
Journal:  PLoS One       Date:  2015-10-01       Impact factor: 3.240

10.  Optimal proteinuria target for renoprotection in patients with IgA nephropathy.

Authors:  Ki Heon Nam; Jeong Hae Kie; Mi Jung Lee; Tae-Ik Chang; Ea Wha Kang; Dong Wook Kim; Beom Jin Lim; Jung Tak Park; Young Eun Kwon; Yung Ly Kim; Kyoung Sook Park; Seong Yeong An; Hyung Jung Oh; Tae-Hyun Yoo; Shin-Wook Kang; Kyu Hun Choi; Hyeon Joo Jeong; Dae-Suk Han; Seung Hyeok Han
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.